ProMIS Neurosciences Inc - Company Profile
Powered by
All the data and insights you need on ProMIS Neurosciences Inc in one report.
- Save hours of research time and resources with
our up-to-date ProMIS Neurosciences Inc Strategy Report
- Understand ProMIS Neurosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company that focuses on the development of therapeutic antibodies and diagnostics for the treatment of neurodegenerative disorders. The companies major products include tests functional assays. The company’s PMN 310, a monoclonal antibody (mAb), designated as its first lead product for development in AD. It uses ProMIS technology, helps in predicting new disease-specific epitopes on the molecular surface of misfolded proteins. Based on ProMIS technology, the company is developing antibody therapeutics and diagnostics targeting Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. ProMIS is headquartered in Toronto, Ontario, Canada.
ProMIS Neurosciences Inc premium industry data and analytics
Products and Services
Products | Services |
---|---|
PMN310, for AD | Diagnostic Services |
TDP43, for ALS | |
Alpha Synuclein, for PD |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In May, the company announced FDA Clearance for Investigation of New Drug Application for PMN310 in Alzheimer’s Disease. |
2023 | Others | In March, the company’s Lead Therapeutic candidate PMN310, Demonstrated Enhanced Selectivity for Toxic Oligomers compared to other Amyloid -Beta-Directed Antibodies. |
2022 | Others | In January, the company announced antibody program for schizophrenia therapy. |
Competitor Comparison
Key Parameters | ProMIS Neurosciences Inc | Idexx Laboratories Inc | DiaSorin SpA | Diagnostica Stago Inc | Inova Diagnostics Inc |
---|---|---|---|---|---|
Headquarters | Canada | United States of America | Italy | United States of America | United States of America |
City | Toronto | Westbrook | Saluggia | Parsippany | San Diego |
State/Province | Ontario | Maine | - | New Jersey | California |
No. of Employees | 6 | 11,000 | 3,278 | - | - |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Eugene Williams | Chairman | Executive Board | 2021 | 63 |
Neil Cashman, M.D. | Chief Scientific Officer; Director | Executive Board | 2014 | 71 |
Daniel E. Geffken | Chief Financial Officer | Senior Management | 2017 | 66 |
Gavin T. Malenfant | Chief Operating Officer | Senior Management | 2021 | 59 |
Larry Altstiel, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2022 | 73 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward